文献速递癫痫

拉考沙胺单药治疗新诊断癫痫不劣于卡马西平缓释片

Efficacy, safety, and tolerability of lacosamide monotherapy versus controlled-release carbamazepine in patients with newly diagnosed epilepsy: a phase 3, randomised, double-blind, non-inferiority trial.
PubMed 文献 · Lancet Neurol · 2016-11-24

这项3期随机双盲非劣效试验纳入888例新诊断癫痫成人患者,比较拉考沙胺与卡马西平缓释片单药治疗。

要点

  • 拉考沙胺单药6个月无发作率非劣效于卡马西平缓释片。
  • 拉考沙胺组严重不良事件7%,因不良事件退出11%,均低于卡马西平缓释片。
  • 拉考沙胺或可作为新诊断成人癫痫的一线单药治疗选择。

核心结论

  • 拉考沙胺单药治疗新诊断成人癫痫满足预设非劣效标准,可能可作为一线单药治疗。

研究设计与样本

  • 3期随机双盲非劣效试验,纳入欧洲、北美及亚太185个癫痫或综合神经中心的888例16岁及以上新诊断癫痫患者。
  • 患者按1:1随机分配接受拉考沙胺单药或卡马西平缓释片每日两次治疗,患者、研究者和试验人员均对分组设盲。
  • 拉考沙胺起始100 mg/日、卡马西平缓释片起始200 mg/日,2周内分别上调至首个目标剂量200 mg/日和400 mg/日,稳定1周后进入6个月评估期。
  • 全分析集为至少服用一次研究药物的患者,拉考沙胺组444例、卡马西平缓释片组442例;符合方案集分别为408例和397例。
  • 试验于2011年4月27日至2015年8月7日进行,注册号NCT01243177。

主要发现

  • 全分析集中拉考沙胺组327例(74%)、卡马西平缓释片组308例(70%)完成6个月治疗且无发作。
  • 治疗中出现的不良事件拉考沙胺组328例(74%)、卡马西平缓释片组332例(75%)。
  • 严重治疗中出现不良事件拉考沙胺组32例(7%)、卡马西平缓释片组43例(10%);导致退出的治疗中出现不良事件分别为47例(11%)和69例(16%)。

关键数值与推荐

  • 预设非劣效标准为组间绝对差-12%和相对差-20%。
  • 主要疗效终点为末次评估剂量稳定后连续6个月无发作的患者比例。

临床怎么用

  • 对于新诊断成人癫痫,拉考沙胺单药可作为一线治疗选项,其疗效非劣效于卡马西平缓释片。
  • 拉考沙胺因不良事件退出比例较低,可结合患者个体情况选择单药方案。

局限性

  • 试验由UCB Pharma资助,可能存在申办方相关偏倚。
  • 非劣效界值较宽(绝对-12%、相对-20%),结果解读需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Further options for monotherapy are needed to treat newly diagnosed epilepsy in adults. We assessed the efficacy, safety, and tolerability of lacosamide as a first-line monotherapy option for these patients. METHODS: In this phase 3, randomised, double-blind, non-inferiority trial, patients from 185 epilepsy or general neurology centres in Europe, North America, and the Asia Pacific region, aged 16 years or older and with newly diagnosed epilepsy were randomly assigned in a 1:1 ratio, via a computer-generated code, to receive lacosamide monotherapy or controlled-release carbamazepine (carbamazepine-CR) twice daily. Patients, investigators, and trial personnel were masked to treatment allocation. From starting doses of 100 mg/day lacosamide or 200 mg/day carbamazepine-CR, uptitration to the first target level of 200 mg/day and 400 mg/day, respectively, took place over 2 weeks. After a 1-week stabilisation period, patients entered a 6-month assessment period. If a seizure occurred, the dose was titrated to the next target level (400 or 600 mg/day for lacosamide and 800 or 1200 mg/day for carbamazepine-CR) over 2 weeks with a 1-week stabilisation period, and the 6-month assessment period began again. Patients who completed 6 months of treatment and remained seizure-free entered a 6-month maintenance period on the same dose. The primary efficacy outcome was the proportion of patients remaining free from seizures for 6 consecutive months after stabilisation at the last assessed dose. The predefined non-inferiority criteria were -12% absolute and -20% relative difference between treatment groups. This trial is registered with ClinicalTrials.gov, number NCT01243177. FINDINGS: The trial was done between April 27, 2011, and Aug 7, 2015. 888 patients were randomly assigned treatment. 444 patients taking lacosamide and 442 taking carbamazepine-CR were included in the full analysis set (took at least one dose of study treatment), and 408 and 397, respectively, were included in the per-protocol set. In the full analysis set, 327 (74%) patients in the lacosamide group and 308 (70%) in the carbamazepine-CR group completed 6 months of treatment without seizures. The proportion of patients in the full analysis set predicted by the Kaplan-Meier method to be seizure-free at 6 months was 90% taking lacosamide and 91% taking carbamazepine-CR (absolute treatment-difference: -1·3%, 95% CI -5·5 to 2·8 relative treatment difference: -6·0%). Kaplan-Meier estimates results were similar in the per-protocol set (92% and 93%; -1·3%, -5·3 to 2·7; -5·7%). Treatment-emergent adverse events were reported in 328 (74%) patients receiving lacosamide and 332 (75%) receiving carbamazepine-CR. 32 (7%) patients taking lacosamide and 43 (10%) taking carbamazepine-CR had serious treatment-emergent adverse events, and 47 (11%) and 69 (16%), respectively, had treatment-emergent adverse events that led to withdrawal. INTERPRETATION: Treatment with lacosamide met the predefined non-inferiority criteria when compared with carbamazepine-CR. Therefore, it might be useful as first-line monotherapy for adults with newly diagnosed epilepsy. FUNDING: UCB Pharma.

来源:Lancet Neurol,查看原文。版权归原作者所有。

引用

  1. Baulac M, Rosenow F, Toledo M, et al. Efficacy, safety, and tolerability of lacosamide monotherapy versus controlled-release carbamazepine in patients with newly diagnosed epilepsy: a phase 3, randomised, double-blind, non-inferiority trial. Lancet Neurol. 2016. PMID: 27889312. doi:10.1016/S1474-4422(16)30292-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。